Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up-Reference-Cited by-同舟云学术

Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

Published:2022-04 Issue:4 Volume:33 Page:362-375
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Oldenburg J.,Berney D.M.,Bokemeyer C.,Climent M.A.,Daugaard G.,Gietema J.A.,De Giorgi U.,Haugnes H.S.,Huddart R.A.,Leão R.,Sohaib A.,Gillessen S.,Powles T.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference101 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Testicular cancer incidence predictions in Europe 2010-2035: a rising burden despite population ageing;Znaor;Int J Cancer,2020

3. Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility;Skakkebaek;Physiol Rev,2016

4. Testicular germ cell tumours;Rajpert-De Meyts;Lancet,2016

5. Family history of cancer and risk of paediatric and young adult's testicular cancer: a Norwegian cohort study;Del Risco Kollerud;Br J Cancer,2019

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS);European Urology Open Science;2024-10

2. Unwrapping the immunological alterations in testicular germ cell tumors: From immune homeostasis to malignancy and emerging immunotherapies;Andrology;2024-09-10

3. miR-21, miR-29a, and miR-106b: serum and tissue biomarkers with diagnostic potential in metastatic testicular cancer;Scientific Reports;2024-08-30

4. Biomarkers of prostate bladder and testicular cancers: current use in anatomic pathology and future directions;Surgical and Experimental Pathology;2024-08-20

5. Konventionell dosierte oder Hochdosis-Salvagetherapie bei rezidivierten Hodentumoren;Aktuelle Urologie;2024-08-06